MORPHINE SULFATE (morphine sulfate) by ICU Medical is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 1992.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
Morphine sulfate is a mu-opioid receptor agonist indicated for pain management via injection. It provides analgesia without a ceiling effect, with dosing titrated to patient response and tolerability. The drug works by binding to opioid receptors in the CNS to modulate pain perception.
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling likely consolidation of brand support and transitional resource allocation.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on morphine sulfate during its LOE-approaching phase offers exposure to defensive commercialization, managed care negotiation, and institutional market dynamics rather than growth-stage innovation. Roles emphasize relationship management, cost-effectiveness, and compliance in a mature opioid market facing generic and biosimilar competition.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo